Big pharmacy to add two more chronic disease medical insurance designated pharmacies
Release time:
2020-09-01
Major Pharmacy added two more chronic disease medical insurance designated pharmacies
News 8# May 7 , Shizhen Pavilion Pharmacy, Shuangxi Pharmacy and Xiaoshun Pharmacy under Jianfeng Major Pharmacy signed a chronic disease service agreement with Jinhua Medical Security Center to formally fulfill the duties and requirements of chronic disease service points and provide high-quality drug purchase service and after-sales service for chronic disease patients. This year, in addition to Shizhen Pavilion Pharmacy, which continues to win the bid, the big pharmacy has added two designated pharmacies for chronic disease medical insurance, Shuangxi Pharmacy and Filial Piety Pharmacy.
After Jinhua Medical Security Center issued the bidding method for the fourth round of designated retail pharmacies for chronic medical insurance in Jinhua city, Jianfeng Pharmacy, according to the implementation rules of this round of bidding, selected3 chain stores from 3 bidding units in Jindong, Jiangnan, Jiangbei and outside the 2nd Ring Road within the streets of the main city, while preparing the bidding applications for 3 chain stores, on the one hand, we will increase the number of chronic disease drugs on the basis of the original varieties of 3 chain stores, interpret the relevant bidding policies in time, and actively do a good job in the bidding of 3 chain stores.
The total number of bidding in this round is 12. Patients with chronic diseases in urban areas can purchase drugs at any chronic disease service point pharmacy according to regulations. The fixed-point period for chronic diseases is 2 and a half years. In the same bidding unit, the one with the highest score is the best, and the winning pharmacy in this round is determined by ranking from high score to low score. 7 May 6 , 3 chain stores under the large pharmacy passed the previous on-site check and spot check of the drug variety catalogue and the chronic disease variety catalogue, submitted the bidding application for the slow protection pharmacy on the same day, and received the bid winning result.
After winning the bid, Xiang Shunjiao, general manager of the large pharmacy, requested the large pharmacy to further strengthen the supervision and assessment of 3chronic disease chain stores in accordance with the relevant policies and regulations of Jinhua Medical Insurance Bureau. Taking advantage of the geographical and operational advantages of 3 chronic disease chain stores, we will actively seek high-quality personnel and physician resources from manufacturers so as to achieve win-win cooperation between the two sides; on the basis of the original hypertension and diabetes, the scope of chronic disease services will be expanded to form a professional chronic disease service site. (Lang Minxiao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page